The results indicated that with the progression of NAFLD, the LPL/FABP4/CPT1 molecules and some cell proliferative markers were generally upregulated since the NASH phase (Figure 1E). The gene discussed is LPL; the disease is metabolic dysfunction-associated steatotic liver disease.